moderate-to-severe – Adis in touch
Skip to content
Adis in touch
A blog from Adis, a leading global provider of drug information.
Search for:
Recent Posts
Artificial Intelligence: organised chaos or chaos ordered?
Is the Search for a Cure for Alzheimer’s Disease Hopeless?
DIA India 2019: Regulatory Trends in Clinical Safety & Pharmacovigilance (An EU perspective).
DIA India 2019 – Keynote Presentation: India Implements Initiatives to Encourage Domestic Clinical Trial Activity and Increase Safety
DIA India: 7th Pharmacovigilance Conference 2019
Recent Comments
Dr Paul Tappenden as… on Call for Papers: Themed Issue…
Dupilumab (Dupixent®… on Dupilumab (Dupixent®): First G…
Durvalumab (IMFENZI®… on Durvalumab (IMFINZI®): Follow…
Dupilumab (Dupixent®… on Dupilumab (Dupixent®): First G…
Baricitinib (Olumian… on Baricitinib (Olumiant™): First…
Archives
April 2019
March 2019
February 2019
December 2018
November 2018
October 2018
July 2018
June 2018
May 2018
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
August 2017
July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
October 2016
September 2016
August 2016
July 2016
April 2016
October 2015
July 2015
June 2015
February 2015
October 2014
September 2014
August 2014
July 2014
May 2014
March 2014
January 2014
October 2013
July 2013
January 2012
Categories
Adis (87)
Adis Journals (93)
Adis Pharmacovigilance (28)
AdisInsight (95)
Uncategorized (2)
Tag: moderate-to-severe
Dupilumab (Dupixent®): CADTH Publishes Negative Recommendation for Reimbursement in Canada
In July 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended not to reimburse dupilumab.[1] Continue reading “Dupilumab (Dupixent®): CADTH Publishes Negative Recommendation for Reimbursement in Canada” →
By Wendy McNeelyin Adis, Adis Journals, AdisInsight July 17, 2018 200 WordsLeave a comment
Dupilumab (Dupixent®): NICE Publishes Positive Final Appraisal Determination
Between March 2017 and January 2018 Dupilumab was approved in four major global regions: the US[1], the EU[2], Canada[3], and Japan.[4] Continue reading “Dupilumab (Dupixent®): NICE Publishes Positive Final Appraisal Determination” →
By Wendy McNeelyin Adis, Adis Journals, AdisInsight July 4, 2018 116 WordsLeave a comment
Baricitinib (Olumiant™): Now also available in the USA
Baricitinib was first approved in the EU in February 2017 for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA);[1] this was followed shortly after by an approval in Japan in July of the same year.[2] Almost a year later, this Janus Kinase (JAK) inhibitor was approved by the US FDA in June 2018.[3] Continue reading “Baricitinib (Olumiant™): Now also available in the USA” →
By Wendy McNeelyin Adis, Adis Journals, AdisInsight, Uncategorized June 12, 2018 192 WordsLeave a comment
Guselkumab (Tremfya™): Follow up Approval in Canada
The first global approval of guselkumab in the USA has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.
Continue reading “Guselkumab (Tremfya™): Follow up Approval in Canada” →
By Wendy McNeelyin Adis, Adis Journals, AdisInsight December 7, 2017 December 14, 2017 164 WordsLeave a comment
Dupilumab (Dupixant®): Follow up Approval in European Union
The recent first global approval[1] of dupilumab in the US has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[2], based on the development milestones tracked in AdisInsight.[3] Continue reading “Dupilumab (Dupixant®): Follow up Approval in European Union” →
By Wendy McNeelyin Adis, Adis Journals, AdisInsight October 11, 2017 172 Words2 Comments
Guselkumab (Tremfya™): First Global Approval – first-in-class biologic treatment option for adult plaque psoriasis
The recent first global approval of guselkumab has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Guselkumab (Tremfya™): First Global Approval – first-in-class biologic treatment option for adult plaque psoriasis” →
By Wendy McNeelyin Adis, Adis Journals, AdisInsight August 22, 2017 August 25, 2017 416 Words1 Comment
Sarilumab (Kevzara™): Follow up Approvals in US and Europe
The first global approval of sarilumab in Canada has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Sarilumab (Kevzara™): Follow up Approvals in US and Europe” →
By Wendy McNeelyin Adis, Adis Journals, AdisInsight July 6, 2017 July 13, 2017 141 Words2 Comments
Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema
The recent first global approval of dupilumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema” →
By Wendy McNeelyin Adis, Adis Journals, AdisInsight June 15, 2017 June 16, 2017 448 Words4 Comments
Powered by WordPress.com.